What is Allakos?
Headquartered in San Carlos, California, Allakos is dedicated to the development of novel therapeutics designed to address significant unmet medical needs in the allergy and immunology sectors. The company's core scientific focus involves modulating receptors on immune effector cells, a mechanism that holds promise for treating conditions such as chronic spontaneous urticaria. By leveraging a sophisticated R&D platform, Allakos aims to redefine the standard of care for patients suffering from debilitating immune-mediated disorders, positioning itself as a high-potential player in the competitive biopharma landscape.
How much funding has Allakos raised?
Allakos has raised a total of $276.4M across 3 funding rounds:
Series A
$42M
Series B
$100M
Stock Offering
$134.4M
Series A (2014): $42M with participation from Alta Partners, RiverVest, and Novo Ventures
Series B (2017): $100M led by Partner Fund Management, 3x5 Partners, Redmile Group, Roche, LifeSci Venture Partners, Alta Partners, Rock Springs Capital, RiverVest Venture Partners, New Enterprise Associates, and Samsara BioCapital
Stock Issuance/Offering (2018): $134.4M, investors not publicly disclosed
Key Investors in Allakos
Alta Partners
Alta Partners is a prominent venture capital firm specializing in healthcare and life sciences, dedicated to supporting entrepreneurs in building impactful companies since 1996.
Redmile Group
Redmile Group LLC is a company that operates in the Venture Capital and Private Equity industry, focusing on high-growth healthcare opportunities.
New Enterprise Associates
Established in 1977, New Enterprise Associates is a global venture capital firm focused on helping entrepreneurs build transformative businesses across various sectors.
What's next for Allakos?
Following the recent capital injection, Allakos is strategically positioned to accelerate the clinical development of its lead product candidate, AK006. The firm is expected to prioritize Phase I trial data analysis and subsequent clinical milestones to validate its therapeutic efficacy. As the company transitions through its current lifecycle stage, the focus will likely shift toward scaling manufacturing capabilities and expanding its intellectual property portfolio. Continued investment in its proprietary receptor-targeting technology will be critical as the firm seeks to establish long-term value in the global biotechnology market.
See full Allakos company page
